Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 456906 dose-ranging phase II trial in NASH with fibrosis
NL-OMON52220Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2021
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of survodutide in metabolic dysfunction-associated steatohepatitis (MASH) and metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Boehringer Ingelheim. Primary endpoint: Primary histological improvement at week 48. Started Sep 2021; status: completed.
02
Drugs
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on NL-OMON52220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52220.